Mistura (O2-O3) no tratamento integrado de cadelas com câncer de mama: perfil oxidativo e qualidade de vida

Abstract

Given the high frequency of malignant mammary tumours, the search for new therapeutic strategies that place growth control and neoplastic dissemination with lower adverse reactions to the patient is growing. In this context, it aimed to evaluate the effects of medicinal ozone as integrative therapy on the oxidative profile, response to treatment and quality of life with mammary neoplasia undergoing conventional chemotherapy with carboplatin. Twenty -five dogs were selected and studied, all with histopathological diagnosis of malignant mammary neoplasia, divided into two experimental groups: GC, composed of carboplatin only (n = 11) and GO3 - consisting of the carboplatin-treated dogs associated with ozone therapy (n = 14). All dogs were submitted to clinical, laboratory, mastectomy, clinical-pathological characterization of the tumour, carboplatin chemotherapy (QT), total oxidizing capacity analysis (TAC), malondialdehyde concentration (MDA), as well as the evaluation of the Survival, rate quality of life scores and graduation of adverse reactions resulting from chemotherapy. Blood samples for antioxidant profile evaluations were collected 48 hours before the first chemotherapy session (moment A), 48h before the fourth session (moment B) and 45 days after the sixth chemotherapy session (moment C). Adverse reactions and quality of life scores were evaluated two h before each session. The results indicated, in the GO3, the highest concentration of red blood cells after the 2nd QT session (p = 0.017) and platelets after the 2nd (p = 0.046), 3rd (p = 0.009) and 6th (p = 0.004) QT sessions; In the GC group, total leukocyte values in the 1st Qt (p = 0.001), 3rd Qt (p = 0.038), 4th (p = 0.030), 5th Qt (p = 0.018) and 6th qt (p = 0.006) and segmented neutrophils after the 1st Qt (p = 0.001), 2nd Qt (p = 0.018), 3rd Qt (P = 0.049), 5th Qt (p = 0.006) and 6th Qt (p = 0.016). There was an increase in quality of life in both groups. Differences were observed between the quality-of-life scores between the groups and within each group, being the largest final scores observed in the GO3 group in the 2nd QT (p = 0.002), 4th QT (p = 0.005), 5th QT (p = 0.005) and 6th QT (p <0.001). Adverse reactions, classified exclusively, were less intense and frequent in the ozone group, such as grade I (p <0.001). Regarding the antioxidant profile, in GO3, at moments B and C, there was a significant increase in TAC (p = 0.017 and p = 0.022) and a reduction of MDA concentration (p = 0.002 and p <0.001). In the analysis of clinical-pathological parameters related to the survival of dogs, there was a significant association in the univariate and multivariate analysis with quality of life, TAC, ozone therapy and MDA. The same ozone therapy analyses showed a significant association with total leukocytes, segmented neutrophils, quality of life, survival, TAC and MDA. The survival rate submitted to integrative treatment was also significantly higher (p = 0.0224) than those treated only with carboplatin. These results, together, indicate that the association between carboplatin and the mixture of oxygen and ozone represents a feasible alternative to complementary treatment for mammary cancer dogs as the patient's antioxidant profile positively reduces the intensity and frequency of Adverse reactions to chemotherapy, which contributes to increased quality of life and survival rate.

Given the high frequency of malignant mammary tumours, the search for new therapeutic strategies that place growth control and neoplastic dissemination with lower adverse reactions to the patient is growing. In this context, it aimed to evaluate the effects of medicinal ozone as integrative therapy on the oxidative profile, response to treatment and quality of life with mammary neoplasia undergoing conventional chemotherapy with carboplatin. Twenty -five dogs were selected and studied, all with histopathological diagnosis of malignant mammary neoplasia, divided into two experimental groups: GC, composed of carboplatin only (n = 11) and GO3 - consisting of the carboplatin-treated dogs associated with ozone therapy (n = 14). All dogs were submitted to clinical, laboratory, mastectomy, clinical-pathological characterization of the tumour, carboplatin chemotherapy (QT), total oxidizing capacity analysis (TAC), malondialdehyde concentration (MDA), as well as the evaluation of the Survival, rate quality of life scores and graduation of adverse reactions resulting from chemotherapy. Blood samples for antioxidant profile evaluations were collected 48 hours before the first chemotherapy session (moment A), 48h before the fourth session (moment B) and 45 days after the sixth chemotherapy session (moment C). Adverse reactions and quality of life scores were evaluated two h before each session. The results indicated, in the GO3, the highest concentration of red blood cells after the 2nd QT session (p = 0.017) and platelets after the 2nd (p = 0.046), 3rd (p = 0.009) and 6th (p = 0.004) QT sessions; In the GC group, total leukocyte values in the 1st Qt (p = 0.001), 3rd Qt (p = 0.038), 4th (p = 0.030), 5th Qt (p = 0.018) and 6th qt (p = 0.006) and segmented neutrophils after the 1st Qt (p = 0.001), 2nd Qt (p = 0.018), 3rd Qt (P = 0.049), 5th Qt (p = 0.006) and 6th Qt (p = 0.016). There was an increase in quality of life in both groups. Differences were observed between the quality-of-life scores between the groups and within each group, being the largest final scores observed in the GO3 group in the 2nd QT (p = 0.002), 4th QT (p = 0.005), 5th QT (p = 0.005) and 6th QT (p <0.001). Adverse reactions, classified exclusively, were less intense and frequent in the ozone group, such as grade I (p <0.001). Regarding the antioxidant profile, in GO3, at moments B and C, there was a significant increase in TAC (p = 0.017 and p = 0.022) and a reduction of MDA concentration (p = 0.002 and p <0.001). In the analysis of clinical-pathological parameters related to the survival of dogs, there was a significant association in the univariate and multivariate analysis with quality of life, TAC, ozone therapy and MDA. The same ozone therapy analyses showed a significant association with total leukocytes, segmented neutrophils, quality of life, survival, TAC and MDA. The survival rate submitted to integrative treatment was also significantly higher (p = 0.0224) than those treated only with carboplatin. These results, together, indicate that the association between carboplatin and the mixture of oxygen and ozone represents a feasible alternative to complementary treatment for mammary cancer dogs as the patient's antioxidant profile positively reduces the intensity and frequency of Adverse reactions to chemotherapy, which contributes to increased quality of life and survival rate.